boston scientific limited Company Information
Company Number
02729626
Next Accounts
Sep 2025
Shareholders
boston scientific international bv
Group Structure
View All
Industry
Other human health activities
+1Registered Address
breakspear park breakspear way, hemel hempstead, hertfordshire, HP2 4TZ
Website
www.bostonscientific.comboston scientific limited Estimated Valuation
Pomanda estimates the enterprise value of BOSTON SCIENTIFIC LIMITED at £244.2m based on a Turnover of £285.3m and 0.86x industry multiple (adjusted for size and gross margin).
boston scientific limited Estimated Valuation
Pomanda estimates the enterprise value of BOSTON SCIENTIFIC LIMITED at £76.3m based on an EBITDA of £10.3m and a 7.42x industry multiple (adjusted for size and gross margin).
boston scientific limited Estimated Valuation
Pomanda estimates the enterprise value of BOSTON SCIENTIFIC LIMITED at £98.8m based on Net Assets of £39.5m and 2.5x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Boston Scientific Limited Overview
Boston Scientific Limited is a live company located in hertfordshire, HP2 4TZ with a Companies House number of 02729626. It operates in the wholesale of other machinery and equipment sector, SIC Code 46690. Founded in July 1992, it's largest shareholder is boston scientific international bv with a 100% stake. Boston Scientific Limited is a mature, mega sized company, Pomanda has estimated its turnover at £285.3m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Boston Scientific Limited Health Check
Pomanda's financial health check has awarded Boston Scientific Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 7 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
7 Weak
Size
annual sales of £285.3m, make it larger than the average company (£8.1m)
£285.3m - Boston Scientific Limited
£8.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 13%, show it is growing at a faster rate (7.3%)
13% - Boston Scientific Limited
7.3% - Industry AVG
Production
with a gross margin of 21.3%, this company has a higher cost of product (32.8%)
21.3% - Boston Scientific Limited
32.8% - Industry AVG
Profitability
an operating margin of 2.4% make it less profitable than the average company (5.4%)
2.4% - Boston Scientific Limited
5.4% - Industry AVG
Employees
with 443 employees, this is above the industry average (30)
443 - Boston Scientific Limited
30 - Industry AVG
Pay Structure
on an average salary of £106.2k, the company has a higher pay structure (£39.1k)
£106.2k - Boston Scientific Limited
£39.1k - Industry AVG
Efficiency
resulting in sales per employee of £644k, this is more efficient (£209.8k)
£644k - Boston Scientific Limited
£209.8k - Industry AVG
Debtor Days
it gets paid by customers after 55 days, this is later than average (42 days)
55 days - Boston Scientific Limited
42 days - Industry AVG
Creditor Days
its suppliers are paid after 1 days, this is quicker than average (25 days)
1 days - Boston Scientific Limited
25 days - Industry AVG
Stock Days
it holds stock equivalent to 34 days, this is in line with average (42 days)
34 days - Boston Scientific Limited
42 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (59 weeks)
0 weeks - Boston Scientific Limited
59 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 65.4%, this is a higher level of debt than the average (39.8%)
65.4% - Boston Scientific Limited
39.8% - Industry AVG
BOSTON SCIENTIFIC LIMITED financials
Boston Scientific Limited's latest turnover from December 2023 is £285.3 million and the company has net assets of £39.5 million. According to their latest financial statements, Boston Scientific Limited has 443 employees and maintains cash reserves of £288 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 285,301,000 | 247,628,000 | 227,684,000 | 195,578,000 | 226,947,000 | 203,714,000 | 191,615,000 | 186,047,000 | 178,117,328 | 158,557,012 | 142,685,929 | 126,142,689 | 118,744,994 | 123,528,596 | 120,845,708 |
Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost Of Sales | 224,446,000 | 197,223,000 | 179,485,000 | 154,531,000 | 178,752,000 | 161,976,000 | 154,288,000 | 141,464,000 | 136,807,790 | 126,271,849 | 112,449,605 | 97,656,039 | 90,855,664 | 101,836,770 | 93,706,658 |
Gross Profit | 60,855,000 | 50,405,000 | 48,199,000 | 41,047,000 | 48,195,000 | 41,738,000 | 37,327,000 | 44,583,000 | 41,309,538 | 32,285,163 | 30,236,324 | 28,486,650 | 27,889,330 | 21,691,826 | 27,139,050 |
Admin Expenses | 54,001,000 | 43,083,000 | 59,518,000 | 38,953,000 | 44,674,000 | 37,618,000 | 33,701,000 | 42,630,000 | 37,916,903 | 29,772,501 | 30,119,226 | 27,502,904 | 25,534,984 | 26,038,075 | 26,970,110 |
Operating Profit | 6,854,000 | 7,322,000 | -11,319,000 | 2,094,000 | 3,521,000 | 4,120,000 | 3,626,000 | 1,953,000 | 3,392,635 | 2,512,662 | 117,098 | 983,746 | 2,354,346 | -4,346,249 | 168,940 |
Interest Payable | 517,000 | 551,000 | 23,000 | 46,000 | 35,000 | 35,000 | 246,000 | 248,000 | 221,051 | 153,907 | 200,402 | 300,503 | 333,874 | 322,551 | 483,876 |
Interest Receivable | 118,000 | 25,000 | 0 | 0 | 11,000 | 5,000 | 2,000 | 15,000 | 6,321 | 6,746 | 23,390 | 45,832 | 18,460 | 69,064 | 67,894 |
Pre-Tax Profit | 6,706,000 | 6,796,000 | 371,000 | 2,048,000 | 3,497,000 | 4,090,000 | 3,382,000 | 2,422,000 | 3,177,906 | 2,365,501 | -59,914 | 729,075 | 2,038,932 | -4,599,736 | -247,042 |
Tax | -2,619,000 | -4,795,000 | -2,375,000 | -1,014,000 | -134,000 | -698,000 | -716,000 | -729,000 | -395,035 | -550,896 | -778,335 | -1,167,029 | -1,422,984 | 436,451 | -981,740 |
Profit After Tax | 4,087,000 | 2,001,000 | -2,004,000 | 1,034,000 | 3,363,000 | 3,392,000 | 2,666,000 | 1,693,000 | 2,782,871 | 1,814,605 | -838,249 | -437,954 | 615,948 | -4,163,285 | -1,228,782 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Profit | 4,087,000 | 2,001,000 | -2,004,000 | 1,034,000 | 3,363,000 | 3,392,000 | 2,666,000 | 1,693,000 | 2,782,871 | 1,814,605 | -838,249 | -437,954 | 615,948 | -4,163,285 | -1,228,782 |
Employee Costs | 47,065,000 | 40,842,000 | 39,134,000 | 35,596,000 | 35,047,000 | 30,937,000 | 26,942,000 | 24,436,000 | 21,760,043 | 16,225,594 | 16,203,426 | 13,978,934 | 12,340,907 | 12,211,291 | 12,419,197 |
Number Of Employees | 443 | 413 | 397 | 384 | 361 | 330 | 323 | 290 | 261 | 236 | 222 | 208 | 192 | 183 | 175 |
EBITDA* | 10,286,000 | 10,261,000 | -8,913,000 | 5,352,000 | 5,745,000 | 6,281,000 | 5,612,000 | 3,891,000 | 4,329,489 | 3,354,272 | 3,591,058 | 4,494,572 | 5,925,820 | -604,700 | 3,616,685 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 4,734,000 | 4,244,000 | 4,226,000 | 3,585,000 | 2,923,000 | 2,754,000 | 2,391,000 | 1,743,000 | 1,733,596 | 1,818,352 | 1,653,915 | 1,945,336 | 1,724,572 | 1,788,553 | 1,829,546 |
Intangible Assets | 4,773,000 | 5,543,000 | 3,435,000 | 4,492,000 | 988,000 | 1,995,000 | 3,117,000 | 4,239,000 | 326,178 | 441,300 | 556,421 | 2,896,322 | 5,792,643 | 8,688,965 | 11,585,286 |
Investments & Other | 21,117,000 | 811,000 | 995,000 | 11,713,000 | 12,682,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 30,624,000 | 10,598,000 | 8,656,000 | 19,790,000 | 16,593,000 | 4,749,000 | 5,508,000 | 5,982,000 | 2,059,774 | 2,259,652 | 2,210,336 | 4,841,658 | 7,517,215 | 10,477,518 | 13,414,832 |
Stock & work in progress | 21,475,000 | 24,402,000 | 20,109,000 | 20,871,000 | 29,358,000 | 16,944,000 | 23,044,000 | 23,008,000 | 23,838,620 | 21,001,352 | 13,823,632 | 11,071,940 | 12,144,597 | 14,631,816 | 5,847,468 |
Trade Debtors | 43,680,000 | 39,182,000 | 30,659,000 | 25,778,000 | 27,449,000 | 31,344,000 | 31,004,000 | 36,077,000 | 26,966,651 | 20,378,841 | 17,510,266 | 15,311,491 | 15,035,361 | 16,619,611 | 14,897,920 |
Group Debtors | 8,194,000 | 13,788,000 | 19,336,000 | 9,350,000 | 13,635,000 | 15,352,000 | 13,825,000 | 6,042,000 | 7,696,220 | 9,377,295 | 10,134,184 | 9,341,000 | 14,332,916 | 3,806,957 | 19,442,606 |
Misc Debtors | 10,091,000 | 7,931,000 | 7,637,000 | 6,428,000 | 5,046,000 | 3,621,000 | 2,874,000 | 1,896,000 | 1,133,364 | 742,721 | 625,727 | 1,150,889 | 1,220,947 | 1,163,541 | 892,824 |
Cash | 288,000 | 3,036,000 | 214,000 | 337,000 | 1,742,000 | 802,000 | 252,000 | 40,000 | 458,039 | 478,017 | 2,350,770 | 1,182,805 | 889,985 | 855,410 | 346,447 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 83,728,000 | 88,339,000 | 77,955,000 | 62,764,000 | 77,230,000 | 68,063,000 | 70,999,000 | 67,063,000 | 60,092,894 | 51,978,226 | 44,444,579 | 38,058,125 | 43,623,806 | 37,077,335 | 41,427,265 |
total assets | 114,352,000 | 98,937,000 | 86,611,000 | 82,554,000 | 93,823,000 | 72,812,000 | 76,507,000 | 73,045,000 | 62,152,668 | 54,237,878 | 46,654,915 | 42,899,783 | 51,141,021 | 47,554,853 | 54,842,097 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 1,210,000 | 339,000 | 380,000 | 590,000 | 853,000 | 459,000 | 89,000 | 123,000 | 28,228 | 93,664 | 29,255 | 77,321 | 599,234 | 166,894 | 116,232 |
Group/Directors Accounts | 26,896,000 | 19,729,000 | 18,339,000 | 10,335,000 | 31,920,000 | 16,123,000 | 25,976,000 | 28,399,000 | 26,290,645 | 17,294,884 | 7,755,396 | 23,725,344 | 10,025,546 | 9,367,923 | 14,145,701 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9,000,000 | 13,690,000 | 0 | 0 | 0 | 0 |
hp & lease commitments | 313,000 | 153,000 | 160,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 45,330,000 | 44,488,000 | 36,936,000 | 41,122,000 | 33,011,000 | 32,848,000 | 31,583,000 | 29,509,000 | 24,162,197 | 20,113,685 | 19,522,579 | 13,026,319 | 11,114,057 | 9,879,510 | 8,751,701 |
total current liabilities | 73,749,000 | 64,709,000 | 55,815,000 | 52,047,000 | 65,784,000 | 49,430,000 | 57,648,000 | 58,031,000 | 50,481,070 | 46,502,233 | 40,997,230 | 36,828,984 | 21,738,837 | 19,414,327 | 23,013,634 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23,223,400 | 23,223,400 | 23,223,400 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 1,056,000 | 659,000 | 835,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 1,056,000 | 659,000 | 835,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23,223,400 | 23,223,400 | 23,223,400 |
total liabilities | 74,805,000 | 65,368,000 | 56,650,000 | 52,047,000 | 65,784,000 | 49,430,000 | 57,648,000 | 58,031,000 | 50,481,070 | 46,502,233 | 40,997,230 | 36,828,984 | 44,962,237 | 42,637,727 | 46,237,034 |
net assets | 39,547,000 | 33,569,000 | 29,961,000 | 30,507,000 | 28,039,000 | 23,382,000 | 18,859,000 | 15,014,000 | 11,671,598 | 7,735,645 | 5,657,685 | 6,070,799 | 6,178,784 | 4,917,126 | 8,605,063 |
total shareholders funds | 39,547,000 | 33,569,000 | 29,961,000 | 30,507,000 | 28,039,000 | 23,382,000 | 18,859,000 | 15,014,000 | 11,671,598 | 7,735,645 | 5,657,685 | 6,070,799 | 6,178,784 | 4,917,126 | 8,605,063 |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | |||||||||||||||
Operating Profit | 6,854,000 | 7,322,000 | -11,319,000 | 2,094,000 | 3,521,000 | 4,120,000 | 3,626,000 | 1,953,000 | 3,392,635 | 2,512,662 | 117,098 | 983,746 | 2,354,346 | -4,346,249 | 168,940 |
Depreciation | 1,685,000 | 1,594,000 | 1,349,000 | 1,478,000 | 1,217,000 | 1,039,000 | 864,000 | 816,000 | 821,733 | 726,489 | 558,451 | 614,504 | 675,152 | 845,228 | 551,423 |
Amortisation | 1,747,000 | 1,345,000 | 1,057,000 | 1,780,000 | 1,007,000 | 1,122,000 | 1,122,000 | 1,122,000 | 115,121 | 115,121 | 2,915,509 | 2,896,322 | 2,896,322 | 2,896,321 | 2,896,322 |
Tax | -2,619,000 | -4,795,000 | -2,375,000 | -1,014,000 | -134,000 | -698,000 | -716,000 | -729,000 | -395,035 | -550,896 | -778,335 | -1,167,029 | -1,422,984 | 436,451 | -981,740 |
Stock | -2,927,000 | 4,293,000 | -762,000 | -8,487,000 | 12,414,000 | -6,100,000 | 36,000 | -830,620 | 2,837,268 | 7,177,720 | 2,751,692 | -1,072,657 | -2,487,219 | 8,784,348 | 5,847,468 |
Debtors | 1,064,000 | 3,269,000 | 16,076,000 | -4,574,000 | -4,187,000 | 2,614,000 | 3,688,000 | 8,218,765 | 5,297,378 | 2,228,680 | 2,466,797 | -4,785,844 | 8,999,115 | -13,643,241 | 35,233,350 |
Creditors | 871,000 | -41,000 | -210,000 | -263,000 | 394,000 | 370,000 | -34,000 | 94,772 | -65,436 | 64,409 | -48,066 | -521,913 | 432,340 | 50,662 | 116,232 |
Accruals and Deferred Income | 842,000 | 7,552,000 | -4,186,000 | 8,111,000 | 163,000 | 1,265,000 | 2,074,000 | 5,346,803 | 4,048,512 | 591,106 | 6,496,260 | 1,912,262 | 1,234,547 | 1,127,809 | 8,751,701 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | 11,243,000 | 5,415,000 | -30,998,000 | 25,247,000 | -2,059,000 | 10,704,000 | 3,212,000 | 1,215,430 | -217,116 | -5,947,509 | 4,042,428 | 10,576,393 | -342,173 | 5,869,115 | -29,577,940 |
Investing Activities | |||||||||||||||
capital expenditure | |||||||||||||||
Change in Investments | 20,306,000 | -184,000 | -10,718,000 | -969,000 | 12,682,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | |||||||||||||||
Financing Activities | |||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 7,167,000 | 1,390,000 | 8,004,000 | -21,585,000 | 15,797,000 | -9,853,000 | -2,423,000 | 2,108,355 | 8,995,761 | 9,539,488 | -15,969,948 | 13,699,798 | 657,623 | -4,777,778 | 14,145,701 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9,000,000 | -4,690,000 | 13,690,000 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -23,223,400 | 0 | 0 | 23,223,400 |
Hire Purchase and Lease Commitments | 160,000 | -7,000 | 160,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 397,000 | -176,000 | 835,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | |||||||||||||||
interest | -399,000 | -526,000 | -23,000 | -46,000 | -24,000 | -30,000 | -244,000 | -233,000 | -214,730 | -147,161 | -177,012 | -254,671 | -315,414 | -253,487 | -415,982 |
cash flow from financing | 9,216,000 | 2,288,000 | 10,434,000 | -20,197,000 | 17,067,000 | -8,752,000 | -1,488,000 | 3,524,757 | 934,113 | 4,965,682 | -2,031,825 | -9,448,304 | 987,919 | -4,555,917 | 46,786,964 |
cash and cash equivalents | |||||||||||||||
cash | -2,748,000 | 2,822,000 | -123,000 | -1,405,000 | 940,000 | 550,000 | 212,000 | -418,039 | -19,978 | -1,872,753 | 1,167,965 | 292,820 | 34,575 | 508,963 | 346,447 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | -2,748,000 | 2,822,000 | -123,000 | -1,405,000 | 940,000 | 550,000 | 212,000 | -418,039 | -19,978 | -1,872,753 | 1,167,965 | 292,820 | 34,575 | 508,963 | 346,447 |
boston scientific limited Credit Report and Business Information
Boston Scientific Limited Competitor Analysis
Perform a competitor analysis for boston scientific limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mega companies, companies in HP2 area or any other competitors across 12 key performance metrics.
boston scientific limited Ownership
BOSTON SCIENTIFIC LIMITED group structure
Boston Scientific Limited has 2 subsidiary companies.
Ultimate parent company
BOSTON SCIENTIFIC CORP
#0018473
BOSTON SCIENTIFIC INTERNATIONAL BV
#0016829
2 parents
BOSTON SCIENTIFIC LIMITED
02729626
2 subsidiaries
boston scientific limited directors
Boston Scientific Limited currently has 3 directors. The longest serving directors include Ms Julie Zeiler (Mar 2010) and Jonathan Monson (Oct 2019).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Ms Julie Zeiler | France | 59 years | Mar 2010 | - | Director |
Jonathan Monson | United States | 51 years | Oct 2019 | - | Director |
Ms Emily Woodworth | United States | 47 years | Aug 2024 | - | Director |
P&L
December 2023turnover
285.3m
+15%
operating profit
6.9m
-6%
gross margin
21.4%
+4.79%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
39.5m
+0.18%
total assets
114.4m
+0.16%
cash
288k
-0.91%
net assets
Total assets minus all liabilities
boston scientific limited company details
company number
02729626
Type
Private limited with Share Capital
industry
86900 - Other human health activities
46690 - Wholesale of other machinery and equipment
incorporation date
July 1992
age
33
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
bestdane limited (July 1992)
accountant
-
auditor
ERNST & YOUNG LLP
address
breakspear park breakspear way, hemel hempstead, hertfordshire, HP2 4TZ
Bank
DEUTSCHE BANK AG
Legal Advisor
BAKER & MCKENZIE
boston scientific limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to boston scientific limited. Currently there are 2 open charges and 0 have been satisfied in the past.
boston scientific limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BOSTON SCIENTIFIC LIMITED. This can take several minutes, an email will notify you when this has completed.
boston scientific limited Companies House Filings - See Documents
date | description | view/download |
---|